- Global biopharmaceutical company – Insmed (NASDAQ:INSM) intends to offer and sell $500M shares in an underwritten public offering.
- Underwriters have a 30-day option to purchase up to an additional 15% of the shares.
- There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- All the shares to be sold in the offering are to be sold by Insmed (INSM).
- The stock price declined 2.2% to $47 on Wednesday during pre-market trade.
